Novadip Biosciences
Watson & Crick Hill
Rue Granbonpré 11
Mont-Saint-Guibert
1435
Tel: 32-10-779-220
Website: http://prosciento.com/
Email: info@novadip.com
About Novadip Biosciences
Founded in 2013 by Dr. Denis Dufrane and Dr. Jean-François Pollet, Novadip Biosciences is a regenerative medicine spin-off company from the University of Louvain (UCL) and St. Luc University Hospital.YEAR FOUNDED:
2013
LEADERSHIP:
CEO and Founder: Jean-François Pollet
Founder and CSO: Denis Dufrane
CMO: Beatrice De Vos
COO: Nicolas Theys
JOBS:
Please click here for Novadip job opportunities.
11 articles about Novadip Biosciences
-
Novadip Biosciences SA announces significant clinical milestones for both of its clinical-stage programs
12/5/2023
Novadip Biosciences SA announced that the first US patient has been implanted with its investigational tissue regeneration product, NVD-003, in its Phase 1b/2a clinical trial in Congenital Pseudarthrosis of Tibia, a rare pediatric bone condition.
-
Novadip Biosciences SA Announces First Pediatric Patient with Congenital Pseudoarthrosis of the Tibia Undergoes Implantation with NVD-003, an Autologous Tissue Regeneration Product, in Phase 1b/2a US/EU Clinical Trial
5/17/2023
Novadip Biosciences SA today announced that the first patient has been implanted with its investigational tissue regeneration product, NVD-003, in its Phase 1b/2a clinical trial treating four patients with Congenital Pseudarthrosis of Tibia (CPT).
-
Novadip Biosciences SA Appoints Judy Ashworth, MD, as Chief Medical Officer
12/27/2022
Novadip Biosciences SA announced the appointment of Judy Ashworth, MD, as Chief Medical Officer of the Company.
-
Novadip Biosciences SA Announces Positive Results from Phase 1/2 Clinical Trial in Patients with Severe Bone Non-Union of the Lower Limb Following Trauma
12/8/2022
Novadip Biosciences SA announced positive data from its Phase 1/2 clinical trial evaluating the safety and clinical activity of its investigational product, NVD-003, in patients with severe bone non-union of the lower limb following trauma.
-
Novadip Biosciences Raises Additional EUR 40 Million Bringing Total Company Funding to EUR 88 Million
11/3/2022
Novadip Biosciences announced that it has raised an additional EUR 40 million in a Series B equity round and non-dilutive funding.
-
Novadip Biosciences announces EUR 19 million Series B financing backed by international investors
10/28/2021
Novadip Biosciences today announced that it has raised €19 million in the first close of a Series B financing
-
Novadip Biosciences reports positive data from phase I study of NVD-001 for spinal fusion
6/15/2021
Mont-Saint-Guibert, June 15, 2021 - Novadip Biosciences, a clinical stage company developing treatments to regenerate impaired tissues in patients with significant unmet medical needs, announced positive final results from a Phase I study of its autologous cell-based product, NVD-001, in patients needing single-level spinal fusion.
-
Novadip Biosciences Presents Clinical Case Study on Next Generation Tissue Regeneration Therapy for Critical Size Bone Reconstruction at EORS Conference
10/2/2019
Novadip Biosciences will present a case study highlighting the results of a scaffold-free, 3-dimensional autologous cell therapy for the treatment of critical size bone reconstruction at the European Orthopaedic Research Society 2019 conference in Maastricht, The Netherlands.
-
Novadip Biosciences presents poster at 11th annual The Bioprocessing Summit
8/12/2019
Presentation to focus on manufacturing platform for tissue engineering
-
NOVADIP BIOSCIENCES appoints Jeff Abbey as CEO
12/12/2018
NOVADIP BIOSCIENCES announces that Jeff Abbey will be appointed chief executive officer, effective early 2019, succeeding Jean-François Pollet.
-
Novadip Biosciences Appoints Eric Paul Pâques As Chairman Of The Board
5/30/2017